ARCA Biopharma

ARCA aims to boost participation by easing stringent enrollment criteria in a study investigating Gencaro in heart failure patients with a favorable response genotype.

NEW YORK (GenomeWeb News) – Arca biopharma today said that Laboratory Corporation of America has told it that the US Food and Drug Administration has accepted LabCorp's investigational device exemption application for a companion diagnostic test for an atrial fibrillation drug under development.

Diaceutics, CAHG Launch Personalized Rx-Focused Marketing, Educational Firm Bioceutics

NEW YORK (GenomeWeb News) – Genome Diagnostics (GenDx) announced this week the launch of KimerDx, a spinout of GenDx focused on developing solid organ transplant tests for monitoring disease relapse and transplant rejection. The new firm is led by Doug Bost as managing director.

ARCA Biopharma, a firm developing genetically targeted treatments for cardiovascular diseases, has appointed Ray Woosley to its board of directors.

Response Genetics, Taiho Extend MDx Services Pact
Response Genetics could receive up to $950,000 for molecular diagnostic testing services provided to Taiho Pharmaceutical related to the development of cancer treatments.

The FDA has approved a trial investigating bucindolol in approximately 3,200 chronic heart failure patients who have a genotype associated with response to the beta-blocker and mild vasodilator.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.